Modelling the US Food and Drug Administration’s accelerated approval program and potential reforms: a case study of the costs and health benefits of cancer treatments
Seminar
This event has now finished.
Event date
Thursday 12 November 2026, 11.15am to 12.15pm
Location
In-person and online
A/019-020, Alcuin A Block, Campus West, University of York
A/019-020, Alcuin A Block, Campus West, University of York
Audience
Open to staff, students (postgraduate researchers only)
Admission
Free admission, booking not required
Event details
Abstract
The U.S. Food and Drug Administration’s (FDA) accelerated approval (AA) program allows the expedited approval of drugs based on intermediate or surrogate endpoints. Drugs granted AA are marketed and reimbursed before their clinical benefit is verified meaning payers spend substantially on drugs that may ultimately prove ineffective. We aimed to evaluate the additional Medicare spending, quality-adjusted life year benefits and net health benefit (NHB) associated with a sample of cancer drugs granted AA between 2012 and 2020. We then estimated the impact of potential policy reforms to the AA program, considering both pathway related policies and health system-related policies. Our results show the cancer drugs were associated with additional Medicare costs of approximately $20.1bn, incremental benefits of 66,805 QALYs compared to the standard of care and a resulting NHB of -134,592 QALYs when valuing one QALY at $100,000. Policies such as limiting the program to the most severe conditions improved the NHB to -62,307 QALYs. Those involving applying discounts to the drug costs improved the NHB to up to 88,761 QALYs. Reforming AA could substantially reduce Medicare spending and improve the net population health of beneficiaries.
If you are not a member of University of York staff and are interested in attending a seminar, please contact alfredo.palacios
About the speaker
Dr Peter Murphy, LSE
Peter is a research fellow at the London School of Economics. His research focuses on economic evaluation, health technology assessment and decision modelling involving both methodological and applied research. He is currently working on an NIHR-funded project researching the economics of cardiovascular medicine.
Peter completed his M.Sc. in health economics at the University of York. He then completed his Ph.D. at the Centre for Health Economics (CHE), University of York and joined the Global Health team at CHE working as a post-doctoral research fellow. Prior to obtaining his Ph.D. he worked as a Health Economics Research fellow in the Centre for Reviews and Dissemination, University of York working extensively on the National Institute for Health and Care Excellence (NICE) technology appraisal programme. He has previously acted as a health economics consultant for the World Health Organization and LSE Health and has published in leading academic journals including The Lancet.
Venue details
Wheelchair accessible